本页面由Tiger Trade Technology Pte. Ltd.提供服务

Outlook Therapeutics, Inc.

0.4250
+0.01192.88%
成交量:64.68万
成交额:27.15万
市值:3,530.36万
市盈率:-0.15
高:0.4350
开:0.4000
低:0.4000
收:0.4131
52周最高:3.39
52周最低:0.3801
股本:8,306.72万
流通股本:6,773.32万
量比:1.55
换手率:0.95%
股息:- -
股息率:- -
每股收益(TTM):-2.8900
每股收益(LYR):-1.7940
净资产收益率:-3.65%
总资产收益率:-209.03%
市净率:-0.92
市盈率(LYR):-0.24

数据加载中...

公司资料

公司名字:
Outlook Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2010
员工人数:
17
公司地址:
111 S. Wood Avenue,Unit #100,Iselin,New Jersey,United States
邮编:
08830
电话:
传真:
- -
简介:
Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司,在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA(贝伐珠单抗-gamma)眼科制剂上市许可,用于治疗湿性年龄相关性黄斑变性,或湿性AMD。

董事

名称
职位
Faisal G. Sukhtian
Chairman of the Board and Director
Robert Charles Jahr
Chief Executive Officer and Director and President
Lawrence A. Kenyon
Chief Financial Officer and Corporate Secretary and Director and Executive Vice President and Treasurer
Ralph H. Thurman
Lead Independent Director
Andong Huang
Director
Gerd Auffarth
Director
Julia A. Haller
Director
Julian Gangolli
Director
Kurt J. Hilzinger
Director
Yezan Haddadin
Director

股东

名称
职位
Robert Charles Jahr
Chief Executive Officer and Director and President
Lawrence A. Kenyon
Chief Financial Officer and Corporate Secretary and Director and Executive Vice President and Treasurer